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CLINICAL STUDY
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ABSTRACT
Objectives: Diffuse enlargements of arteriovenous dialysis fistulas customarily attributed to
either excessive arterial inflow or central outflow stenosis. The relationship between volume
status and clinically enlarged (arteriovenous) fistula (CEF) formation in end-stage renal disease
(ESRD) patients is not well understood.
Methods: We assessed the pre-dialysis bioimpedance spectroscopy-measured percentage of
overhydration (OH%) in 13 prevalent dialysis patients with CEF development and negative angi-
ography and compared the results with those of 52 control dialysis patients (CONTR). All patients
were prevalent ESRD patients receiving thrice-weekly maintenance hemodiafiltration at an
academic outpatient dialysis unit.
Results: 10/13 CEF patients had OH% 15% as compared to 20/52 control patients (Chi square p:
.02). The degree of OH% was 20.2±7.4% among the CEF vs. 14.4±7.1% in the control group
(Student’s t-test p: .01), representing 4.2±3.2 vs. 2.8±1.6 L of excess fluid pre-dialysis (p: .03).
Patients with CEF development took an average of 1.7±1.4 vs. 0.8±0.8 (p: .002) antihypertensive
medications compared to the CONTR patients, yet their blood pressure was higher: 156/91 vs. 141/
78mmHg (systolic/diastolic p: .03<.0001). We found no difference in fistula vintage, body mass
index, age, diabetes status, or diuretic use. The odds ratio of having a CEF in patients with 15%
OH status was 5.3 (95% CI: 1.3–21.7; p: .01), the Number Needed to Harm with overhydration was 4.
Conclusions: There is an association between bioimpedance spectroscopy-measured overhy-
drated clinical state and the presence of CEF; either as an increased volume capacitance or as a
potential cause.
ARTICLE HISTORY
Received 29 January 2019
Revised 21 March 2019
Accepted 27 April 2019
KEYWORDS
Bioimpedance spectroscopy;
blood pressure; body
composition; end-stage
renal disease; megafistula;
volume overload
Introduction and background
For decades, arterio-venous fistulas (AVFs) have been
deemed the primary and desired dialysis access for
hemodialysis [1], with the successful creation and main-
tenance of AVFs remaining Achilles’ heel of hemodialy-
sis. Most dialysis fistulas fail by stenosis and clotting,
representing the principal cause of access loss in hemo-
dialyzed patients, more commonly occurring in dia-
betics [2] or those with higher hemoglobin [3]. Early
failure of arteriovenous dialysis access occurs at a rate
of about 17.5% [4] to 23% [5] and the overall one-year
primary patency rate is about 60%. Most efforts to
maintain and salvage fistulas have focused so far on
the preservation of blood flow in the arterial inflow or
venous outflow tracts.
Another, albeit much less common mechanism of
hemodialysis access failure is the development of fistu-
las with excessively high flow and large diameters,
also known as megafistulas [6], most commonly origi-
nating from the brachio-cephalic location. Established
risk factors for megafistulas are wide arterio-venous
anastomoses with large blood flow rates or a relative
narrowing of the draining vein in the venous circula-
tion. Megafistula formation is most commonly recog-
nized by an excessive blood flow and clinically
confirmed by the Nicoladoni-Branham maneuver. The
suggested criteria include an increased blood flow
greater than 2.2 L/min, increased cardiac output and
index, increased (>20%) cardio-pulmonary recircula-
tion and hypertrophied feeding artery [6,7].
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Another working definition of megafistula simply
refers to the ultrasonically measured blood flow rate
within the fistula. ‘Although it is uncertain as to why
some patients develop a megafistula, altered hoop
stress (circumferential stress) almost certainly plays a
role’ [8]. The exact relationship between volume status
and enlarged fistula formation is, nonetheless, cur-
rently insufficiently understood. Objective assessment
of volume status in end-stage renal disease (ESRD)
remains challenging and persisting chronic volume
overload may contribute to poor BP control [9,10], vas-
cular stiffness [10,11], and decreased survival [12–15].
Bioimpedance monitoring is an emerging gold stand-
ard methodology to assess not only body composition
[16–18] but to assess the exact degree of volume sta-
tus in dialysis patients [14–16,19]. As the relationship
between volume status, antihypertensive drug use sta-
tus and an enlargement of AVF is not well understood,
we investigated whether volume overload may repre-
sent an additional risk factor for these redundant vas-
cular enlargements.
Methods
This was a case-control study approved by the Ethics
Committee of the Hungarian Health Ministry (equiva-
lent for an Independent Review Board) (TUKEB 3032-1/
2015/EKU) and Fresenius Medical Care as the dialysis
provider in Hungary. The study conformed to the
Helsinki Declaration as developed by the World
Medical Association. The data used for the study were
obtained during routine care of maintenance dialysis
at the Fresenius Medical Care facilities, within the
premises of and affiliated with Semmelweis University
in Budapest, Hungary. All patients received thrice
weekly maintenance hemodiafiltration using a post-
dilution fluid replacement method, aiming at a single-
session Kt/V of 1.4 and a replacement fluid volume of
21 L [20].
All of our patients routinely undergo bimonthly
pre-dialysis fluid status evaluations at the designated
medical care facility by using a multi-channel bioim-
pedance spectroscopy apparatus (BCM – Body
Composition Monitor, Software version 3.2; Fresenius
Medical Care, Bad Homburg, Germany) as part of our
standard clinical practice. The etiology of the proband
group’s ESRD was heterogeneous including PCKD (1),
urological anomalies (1), nephrectomy because of
renal cell carcinoma (2), presumably hypertension (1),
diabetes (3), glomerulonephritis (2), and unknown. We
have previously described the measurement method
[16]; however, it shall be added that we measured the
patients’ fluid compartments by positioning them flat
on their backs and placing two conductive electrodes
on their hands and ankles on the same side at the
same time. With this method, we measured their total
body water (TBW), extracellular water (ECW), intracel-
lular water (ICW), and overhydration (OH) levels in lit-
ers and acquired the percentage (OH%) of the excess
fluid that is greater than the anticipated ECW. The val-
idation of the bioimpedance methods for measuring
fluid spaces has been done historically with various
isotopes (of potassium, bromide, hydrogen), tagged
albumin and DEXA scans and reviewed earlier in
details [21].
Our goal was to define pre-dialysis BCM-measured
OH% in 13 prevalent chronic dialysis patients with
CEF. The diagnosis of CEF was established on clinical
exam, with excessive and torturous dilatations of
arteriovenous fistula observed throughout its course in
the extremity; these were typically easy to palpate and
traceable to the shoulder. We did not have the means
to measure blood flow in the fistulas; consequently,
the diagnosis of ultrasonography-determined megafis-
tula could not be made with certainty and the diagno-
sis of clinically enlarged AVF was made purely on
clinical grounds, by the consensus of the nephrologists
involved in the clinical care of the cohort. Due to this
lack of diagnostic rigor, we refer to these fistulas as
clinically enlarged fistulas (CEFs). All CEF subjects had
negative angiographies performed earlier by a dedi-
cated interventional radiologist and definitively ruled
out for proximal outflow stenosis. We compared these
patients with 52 consecutive control dialysis patients
without enlarged fistula formation on clinical grounds
but no further testing (Doppler ultrasound or angiog-
raphy) was performed. We tabulated the patients’
demographic characteristics as well as their blood
pressures and blood pressure medication numbers.
For the comparison of continuous data, we utilized
Student’s t-tests and for categorical data, we explored
statistical significance with two-tailed Fisher’s exact
test statistics.
Results
The characteristics of the patients are depicted in
Table 1. The CEF as well as the control patients’ data
passed the normality test for the Gaussian distribu-
tion when tested by the D’Agostino and Pearson
omnibus normality test, the Shapiro normality test,
and the Kolmogorov–Smirnov test for normality.
There was a statistically significant male predomin-
ance (84.6% vs. 51.9%; p: .03) among the subjects
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with CEFs, but they did not differ in age, dialysis vin-
tage, prevalence of diabetes mellitus or even the
amount of residual urine volume from controls.
Importantly, however, the CEF patients had higher
blood pressure, took more antihypertensive medica-
tions and were significantly more overhydrated
(p< .01 for all). The degree of overhydration, when
expressed in liters showed 1.4 L of excess extracellular
fluid (Student’s t-test p: .03; Mann–Whitney p: .06)
among the subjects with CEF. Moreover, when the
degree of volume overload was expressed as a % of
OH, the difference became striking (Student’s t-test p:
.01; Mann–Whitney p: .01) with a clear dichotomy at
15% OH, an established cutoff point for future
adverse events [12,22–24]. This is also illustrated by
Figure 1’s scatter plots, demonstrating the medians
and standard deviation intervals for both groups. Our
data were also examined in a categorical fashion rela-
tive to the 15% OH cutoff (Table 2). The majority of
CEF patients were in the >15% OH category with the
two-tailed Fisher’s exact test of association significant
(p: .02). The unadjusted odds ratio of those with a
CEF being in fluid excess was 5.3 (95% CI: 1.3–21.7;
p: .01; the Number Needed to Harm was 4).
Discussion
The presence of a high-flow hemodialysis fistula is
associated with multiple adverse outcomes. These
include steal syndrome [25], exotic complications such
as hemothorax [26] or pulmonary embolism [27], and
the impairment of cardiac function with high-output
heart failure resulting from a large proportion a large
proportion of the cardiac output recirculated through
the enlarged fistulas [22,28,29]. While our working def-
inition of CEF in our study was not harmonized to the
diagnosis of ultrasonography-defined megafistula with
high overall flow nor did we perform the Nicoladoni-
Branham maneuver, our study entertains yet another
striking possibility contributing to enlargement of
arteriovenous accesses; the one of chronic salt-water
overload. Only recently, exact technology with bioim-
pedance analysis become available for the daily rou-
tine care of ESRD patients, to offer reliable and
repeated measures of volume status with a minimized
Table 1. Demographics and results comparing hemodialysis patients with and without a clinically
enlarged fistula.
Clinically enlarged fistulas (n: 13) Control (n: 52) p
Gender (M:F) 84.6% 51.9% .03
Age (years) 51.1 ± 14.7 59.0 ± 14.7 .09
Dialysis vintage (years) 5.3 ± 2.4 4.8 ± 3.8 .62
Diabetes (%) 8 23 .22
Residual urine volume (mL/day) 274 ± 218 169 ± 295 .23
Number of antihypertensive medications 1.77 ± 1.4 0.80 ± 0.8 .002
Diuretics use (%) 15.3 9.6 .56
Body mass index (kg/m2) 25.1 ± 6.5 26.7 ± 5.7 .40
Systolic blood pressure (mmHg) 156 ± 24.5 141 ± 20.8 .003
Diastolic blood pressure (mmHg) 91 ± 10.9 78 ± 9.7 <.0001
OH (L) 4.2 ± 3.2 2.8 ± 1.6 .03
OH% 20.2 ± 7.4 14.4 ± 7.1 .01
EC (L) 19.7 ± 6.0 20.2 ± 18.7 .92
OH: overhydration: OH%: percent overhydration: EC: extracellular fluid volume.
When continuous data are shown, the means ± standard deviation is displayed.
Figure 1. Comparison of those with and without a clinically
enlarged arteriovenous fistula (CEF) with respect to the bioim-
pedance-measured fluid overhydration. The two populations’
percent-overhydration (n: 13 and n: 52) mean ± standard devi-
ation is depicted by the horizontal lines.
Table 2. Results comparing those with and without a CEF in
a 2 2 table for Fisher’s exact test (p: .02).
Data analyzed CEFþ CEF– Total
OHþ 10 20 30
OH– 3 32 35
Total 13 52 65
CEF: clinically enlarged (arteriovenous) fistula; OH: overhydration; overhy-
dration (OH) was dichotomized at a 15% excess of extracellular fluid;
CEFþ: patients with a CEF; CEF–: patients without a CEF; OHþ: overhy-
drated; OH–: not overhydrated.
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burden and cost for the dialysis networks [9,14,15].
Our study shows that patients with a CEF have excess
fluid of about 1.4 L over the control group. While this
quantity does seem small, it is important to note that
10 out of 13 patients with a CEF had severe pre-dialy-
sis volume overload as compared to only 20 of the 52
patients without CEF. We deemed fluid overload as
‘severe’ when the degree of overhydration (OH%) was
greater than 15% [12,19]. Expressing fluid overload in
liters is important to help individual patients under-
stand target weight goals during renal replacement
therapy, whereas expressing OH in percent is import-
ant for prognosis and securing comparability among
clinical studies. As Wizemann et al. [12] showed,
hemodialysis patients’ mortality is strongly affected
when this threshold is met or exceeded. Interestingly,
Wizemann’s study also showed that the presence of
hypertension may be somewhat protective (hazard
ratio: 0.98, p: .01) from mortality. Thus, we used the
15% OH cutoff to define the tolerance for fluid excess.
The sustained fluid excess was not related to interdia-
lytic weight gain – it hardly ever is – but rather to the
inadequate determination and failure to reach the esti-
mated dry weight [15]. In this particular cohort, we
routinely observed that patients with CEF have stead-
fastly refused physician-recommended dry weight
reduction and insisted that their weight be maintained
at the level they deemed appropriate for themselves.
There could be many reasons why these patients
refused dry weight reduction; one possible explan-
ation is the relatively long vintage (5.3 years) with the
patients’ sense of empowerment of ‘knowing it better’.
Also, the long vintage, could have contributed merely
to the development of CEF, given so many cannula-
tions over the years. In the past, we have demon-
strated that one possible reason for fluid overload in
dialysis patients is due to the difficulties reaching tar-
get net ultrafiltration goals while taking multiple anti-
hypertensive drug medications [16]. In our current
study, the linear regression analysis coefficient was
0.673 (p< .0001), between the number of antihyper-
tensive medications and the amount of excess fluid (in
liters), as measured by bioimpedance. Further, there
was a strong correlation (r¼ 0.54, p< .0001) between
the number of antihypertensive medications and the
degree of fluid overload. Antihypertensive medications
pose a risk of intradialytic hypotension, cramping and
does appear to interfere with adequate ultrafiltration
[9,16,30,31]. Indeed, this CEF patient cohort was taking
a significantly larger number of antihypertensive medi-
cations (1.7 vs. 0.8; p: .002) and they were – perhaps
consequently – more fluid overloaded. The use of
diuretics did not appear to be protective. Our study
reinforces the importance of validated technologies in
determining the optimal target weight in ESRD
patients as they are at risk for both hypo- and hyper-
volemia during treatment, if to rely on clinical assess-
ment alone [9,16,30,31].
The question of interest raised by our study is
whether this measured fluid excess is simply a measure-
ment capacitance (the cumulative volume of enlarged
fistulas) or the cause or exacerbating factor for the
development of the CEF. The fact that these patients
were taking more antihypertensive medications indi-
cates a strong possibility of long-standing fluid over-
load, in keeping with the slow speed of enlarged fistula
formation. As shown in Table 1, prescribing more anti-
hypertensive drugs may have been the rule for these
subjects, further aggravating the tendency to both fluid
overload and potential CEF formation. While conven-
tional treatment for these high-flow accesses is inflow
restriction [6,32], the treatment may also involve opti-
mizing fluid status.
Our study has several limitations. As CEF formation
is a rare event, we compensated for the low number
of index patients by ensuring that the comparator
control group had plenty of patients, four times as
many as the group with the condition. The lack of
ultrasound-measured fistula flow determination was
an obvious limitation of our study. We also did not
perform cardiac ultrasound investigations as the focus
of the study was fluid excess and its association with
the presence of fistula enlargement, even though per-
sisting fluid excess does have cardiac consequences
as well. We have no information on previous endovas-
cular interventions. Most importantly, the largest limi-
tation of this study was the case-control design and
observational nature of the project; therefore, a defini-
tive conclusion cannot be drawn at this time. On the
other hand, it would have been ethically impossible
to perform a prospective study of fluid overloaded
patients. Future studies need to explore this relation-
ship further and extend these investigations to
include measurements of cardiovascular health and
cardiac output among these patients.
Conclusions
While the observational nature of this study does not
permit to imply causality, we observed a striking associ-
ation between CEF formation and OH in a prevalent
cohort of otherwise stable ESRD patients. This novel
association may represent yet another consequence of
poorly controlled volume status in ESRD and additional
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studies needed to provide independent verification.
Future trials need to consider the presence of fistula
enlargement when prospectively evaluating bioimpe-
dance analysis and volume status among those being
started on or receiving maintenance dialysis.
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